Insulin Resistance and Adiponectin Levels in Drug-Free Patients with Schizophrenia: A Preliminary Report

Cohn, Tony; Remington, Gary; Zipursky, Robert B.; Azad, Azar; Connolly, Philip; Wolever, Thomas M. S.

doi:10.1177/070674370605100608

Cited by 92 publications

(70 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There is a body of evidence to suggest that schizophrenia itself may be linked to an increased risk of glucose dysregulation, although the data remain contradictory on this point. [46][47][48][49][50] More consistent are the findings that, at least prior to the onset of FEP, schizophrenia is not associated with increased risk of obesity. [48][49][50][51][52][53] Indeed, several reports have suggested that an FEP is associated with lower BMI values than seen in control subjects.…”

Section: The Association Between Schizophrenia and Obesitysupporting

confidence: 54%

Beyond Pharmacotherapy: Understanding the Links between Obesity and Chronic Mental Illness

et al. 2012

Self Cite

View full text Add to dashboard Cite

While differences in weight-gain potential exist, both between and within classes of psychiatry medications, most commonly used atypical antipsychotics, mood stabilizers, and antidepressants result in some degree of weight gain. This is not new information and it requires an understanding of the tolerability profiles of different treatments and their goodness of fit with specific patient phenotypes. However, this iatrogenic association represents only a piece of this obesity-mental illness dyad. The complex interplay between psychiatric illness and weight involves neurobiology, psychology, and sociological factors. Parsing the salient variables in people with mental illness is an urgent need insofar as mortality from physical health causes is the most common cause of premature mortality in people with chronic mental illness. Our review examines issues associated with common chronic mental illnesses that may underlie this association and warrant further study if we hope to clinically intervene to control this life-threatening comorbidity. W W WBien que les différences de potentiel de gain de poids existent, à la fois entre les classes de médicaments psychiatriques et au sein de celles-ci, les antipsychotiques atypiques, les psychorégulateurs et les antidépresseurs les plus fréquemment utilisés entraînent à un certain degré une prise de poids. Cette information n'a rien de neuf et elle demande une compréhension des profils de tolérabilité de différents traitements et de leur qualité d'ajustement aux phénotypes spécifiques du patient. Cependant, cette association iatrogène ne représente qu'une pièce de ce tandem obésité-maladie mentale. L'action réciproque complexe entre la maladie psychiatrique et le poids met en jeu la neurobiologie, la psychologie et les facteurs sociologiques. L'analyse des variables prépondérantes chez les personnes souffrant de maladie mentale est un besoin urgent pour autant que la mortalité attribuable à des causes de santé physique est la cause la plus commune de mortalité prématurée chez les personnes souffrant de maladie mentale chronique. Notre étude examine les questions associées aux maladies mentales chroniques communes qui peuvent sous-tendre cette association et justifient plus de recherche si nous souhaitons intervenir cliniquement pour contrôler cette comorbidité qui met la vie en danger.

show abstract

Section: The Association Between Schizophrenia and Obesitysupporting

confidence: 54%

Beyond Pharmacotherapy: Understanding the Links between Obesity and Chronic Mental Illness

et al. 2012

Self Cite

View full text Add to dashboard Cite

show abstract

“…These proinflammatory agents are thought to induce oxidative stress thereby exacerbating underlying pathological processes leading to dyslipidemia, glucose intolerance, insulin resistance, and endothelial dysfunction that are common in obesity and type II diabetes mellitus (T2DM) (Sonnenberg et al, 2004). Previous cross-sectional studies found both higher (Togo et al, 2004) and lower (Richards et al, 2006) adiponectin levels in patients treated with olanzapine compared to healthy controls as well as lower levels in untreated patients compared to controls (Cohn et al, 2006). One additional study found no change in adiponectin after 4 weeks of olanzapine treatment (Hosojima et al, 2006).…”

Section: Introductionmentioning

confidence: 99%

Early treatment-related changes in diabetes and cardiovascular disease risk markers in first episode psychosis subjects

Graham

Cho

Brownley

et al. 2008

Schizophrenia Research

View full text Add to dashboard Cite

Objective-To examine prospective changes in cardiovascular disease (CVD) and type-2 diabetes risk factors in young adult first episode psychotic (FEP) patients treated with second generation antipsychotic medications.Methods-At baseline, fasting serum and anthropometric measures were obtained from 45 FEP patients and 41 healthy adults (controls) of similar age, ethnicity and sex; sixteen of the FEP patients remained on the same antipsychotic medication and were available for a second blood draw at 24 weeks of treatment. Serum was assayed for glucose, insulin, triglycerides, total cholesterol and high and low density lipoproteins (HDL, LDL), adiponectin, leptin, interleukin 6, E-selectin and VCAM-1. Wilcoxon nonparametric tests were used to compare risk markers between the FEP and control group at baseline and to evaluate pre-post treatment changes within the FEP group.Results-At baseline, the distributions of risk marker values were similar between the two groups and the percentages of FEP patients and healthy controls who were overweight/obese, dyslipidemic, hyperglycemic, and hyperinsulinemic did not differ. At 24 weeks, compared to baseline, FEP patients showed significant increases in BMI (p=0.0002), glucose (p=0.0449), insulin (p=0.0161), cholesterol (p=0.0129), leptin (p=0.0215), and E-selectin (p=0.0195), and a decrease in adiponectin (p=0.0371).Conclusions-Among patients with first episode psychosis, 6-month treatment with second generation antipsychotics is associated with the exacerbation of pre-existing and emergence of new CVD and diabetes risk factors.

show abstract

“…Some [5][6][7][8] but not all 9 studies have found that compared with matched controls, newly diagnosed, antipsychoticnaive patients with nonaffective psychosis have an increased prevalence of impaired glucose tolerance, diabetes, or increased insulin resistance. This conclusion is far uncertain because some of these studies were weakened by problems in matching or possible confounding by hypercortisolemia.…”

mentioning

confidence: 99%

Schizophrenia as A Systemic Disease

Kirkpatrick¹

2009

Schizophrenia Bulletin

View full text Add to dashboard Cite

Insulin Resistance and Adiponectin Levels in Drug-Free Patients with Schizophrenia: A Preliminary Report

Cited by 92 publications

References 12 publications

Beyond Pharmacotherapy: Understanding the Links between Obesity and Chronic Mental Illness

Beyond Pharmacotherapy: Understanding the Links between Obesity and Chronic Mental Illness

Early treatment-related changes in diabetes and cardiovascular disease risk markers in first episode psychosis subjects

Schizophrenia as A Systemic Disease

Contact Info

Product

Resources

About